forecast
First drug generates $400 million in launch year
Argenx's first approved drug generated about $400 million in its first year of launch and is growing strongly, supporting a projection of $7 to $8 billion in revenue from the first four programs within five to seven years.
forecastpending
Speaker
JuliaEvidence Quote
“you can see how it can become $7 billion, $8 billion opportunity within next five, seven years”
Created: 11/17/2026, 3:39:21 AM
Your notes
Loading notes...